Member Info for ParanoiaBlue

- Revenues up 1.3% to £2.48 million (H1 2009: £2.45 million) - Cash generation maintained with EBITDA* of £238,000 (H1 2009: £291,000) - Continuing profitability with net profit* of £122,500 (H1 2009: £159,800) - Cash flow from operations robust at £245,000 (H1 2009: £381,000) - Growth continues into the second half of 2010, with July's revenue a record for the Company [* excluding share based payment charge]

“Our performance in the first half of 2010 held up nicely despite a slow start to the year because of issues associated with the global economy, inclement weather, and volcanic ash. While our competitors have released disappointing results in the comparative period, we have remained profitable and cash generative. This robust performance has allowed us to make some significant investments. The acquisition of our US-based rival, Apredica, which was preceded by Apredica's acquisition of Cellumen's intellectual property and assets, represents a transformational event for the Company. It gives the Company an operational base in the US (the largest market for our combined services), immediate entry and credibility in the in vitro toxicology market, plus advanced, proprietary toxicology technology. These acquisitions, along with our soon-to-open UK toxicology laboratory, enable the Company to immediately become a major player in the in vitro toxicology market, which we believe is the highest opportunity sector of pre-clinical research today. Our immediate focus is to rapidly integrate our acquisitions, and then focus on cross-selling opportunities of our existing and new offerings to our now much-expanded customer base. These opportunities, along with a record start to the second half, give us increased confidence in the outlook despite market conditions remaining challenging.”

http://www.investegate.co.uk/Article.aspx?id=201008120700209505Q

..folks!!

… so far :)

Now into an extended auction. I wonder if there is anything in the air?

..another positive day. To my mind this one should be in three digits. ATB

Cluff Gold received an unsolicited offer in February but the share price has fallen back to 73p since the bid discussions ended. At this level, the Africa-focused gold miner is undervalued, with the share price taking no virtually no account of the Sierra Leone mine Baomahun's short or long-term potential. Buy says the Mail on Sunday.

Midas verdict: Cluff received an unsolicited offer back in February and talks drifted on until the end of May. During that time, the share price reached 102p. Since bid discussions ended, the price has fallen back to 73p. At this level, the stock is undervalued, taking virtually no account of Baomahun's short or long-term potential. Buy.

I can’t find any reason for the rise, but it is very welcome. In fact we could do with a lot more. :)

http://www.investegate.co.uk/Article.aspx?id=201007210700136329P

…if .there has been any institutional selling, causing this recent SP drop.

I think there is a bit of naivety, in the air. More and more bad news is coming out of the US, EU & UK – Surprise! surprise! If the various “glubbermints” decide to “crank up the printing presses” i.e more QE, yet again, then watch gold, and gold shares, fly! Keep the faith!

..a silly spread!

...that didn't last too long.

Nice little tick-up, today

Yes, I'm still, here. Most are still in the red, so I’m holding out for a while longer, as there is good potential, here. NB Most gold shares have been, somewhat weak, recently.

http://www.investegate.co.uk/Article.aspx?id=201007141505203553P

"In the current year, Cyprotex has experienced a strong second quarter and this momentum has continued into July. The Company's revenue and EBITDA performance is in line with market expectations. Furthermore, the Company will open a new laboratory in the coming weeks which will double capacity and allow the launch of our new toxicology offerings."

http://www.investegate.co.uk/Article.aspx?id=201007140700072951P